RECRUITING

HEME Home Transfusion Program

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.

Official Title

Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial

Quick Facts

Study Start:2025-09-10
Study Completion:2029-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06487247

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Oreofe Odejide, MD, MPH
CONTACT
617-632-6864
Oreofe_Odejide@dfci.harvard.edu
Sunny Rosenthal, MPH
CONTACT
857-215-2820
sjrosenthal@mgb.org

Principal Investigator

Oreofe Odejide, MD, MPH
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Brigham and Women's Hospital
Boston, Massachusetts, 02215
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Oreofe Odejide, MD, MPH, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09-10
Study Completion Date2029-05-31

Study Record Updates

Study Start Date2025-09-10
Study Completion Date2029-05-31

Terms related to this study

Keywords Provided by Researchers

  • Leukemia
  • Myeloma
  • Myelodysplastic Syndromes
  • Hematologic Malignancy
  • Hematologic Diseases
  • Lymphoma

Additional Relevant MeSH Terms

  • Leukemia
  • Myeloma
  • Myelodysplastic Syndromes
  • Hematologic Malignancy
  • Hematologic Diseases
  • Lymphoma